UPDATE 1-China rejects patent linked to Gilead hepatitis C drug By: Reuters: Company News June 19, 2015 at 04:24 AM EDT * Sovaldi controversial due to its high cost of $1,000 per pill (Recasts and writes through with details of the drug) Read More >> Related Stocks: Gilead Sciences